Navigation Links
Receptos to Deliver Scientific Presentation at Digestive Disease Week 2012 about the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease

SAN DIEGO, May 18, 2012 /PRNewswire/ -- Receptos Inc. today announced that company personnel will deliver a scientific podium presentation about RPC1063 at the Digestive Disease Week (DDW) annual meeting at 9 a.m. PDT on Sunday, May 20, 2012 at the San Diego Convention Center in San Diego, California. DDW attracts thousands of physicians, researchers, and academics from around the world to share the latest research in gastrointestinal health topics, for which DDW is the premier scientific conference. Based on an abstract entitled "A small molecule S1P1 receptor agonist with significant efficacy in animal models of inflammatory bowel disease (IBD)," Receptos scientific personnel will discuss positive preclinical data with RPC1063 in two distinct in vivo models of IBD.

"Based on exciting data from these preclinical studies, as well as data from a recently completed Phase 1 clinical safety study, Receptos will initiate a Phase 2 clinical trial with RPC1063 in 2012 in inflammatory bowel disease," said Faheem Hasnain, President and Chief Executive Officer of Receptos. "The acceptance of these preclinical efficacy data for presentation at DDW underscores the need for efficacious oral treatments for the therapeutic treatment of IBD and the excitement on the part of scientific and clinical investigators to explore the novel profile of RPC1063 in patients suffering from this debilitating disease."

About RPC1063 and S1P1 Agonists
RPC1063 is a novel, differentiated sphingosine 1-phosphate 1 receptor (S1P1) selective agonist exhibiting picomolar potency that is effective in rodent models of both multiple sclerosis (MS) and inflammatory bowel disease (IBD), and possesses an excellent safety profile in non-clinical toxicology studies. Receptos has completed a Phase 1 clinical safety study with RPC1063 under a US IND that supports the desired differentiation profile and establishes justification for initiation of MS and IBD clinical efficacy trials in 2012. S1P1 is a G protein-coupled receptor (GPCR) that binds the lipid signaling molecule sphingosine 1-phosphate (S1P). S1P is a circulating lipid that binds to five GPCRs termed S1P1-5. S1P1 selectively regulates physiological functions in the immune and cardiovascular systems, including immune cell trafficking and the maintenance of endothelial integrity. In autoimmune disorders, S1P1 agonism works by selectively sequestering circulating lymphocytes, blunting the underlying cause of disease.

About Receptos
Receptos is a biopharmaceutical company developing autoimmune therapeutic candidates through information‐driven drug discovery, including GPCR structure determination. The company's lead program, RPC1063, is a best‐in‐class S1P1 small molecule agonist candidate for autoimmune indications. The S1P1 program is supported by the company's proprietary high resolution protein crystal structure of the S1P1 receptor. Receptos has established partnerships for its GPCR structure determination technology platform with Eli Lilly, Ono Pharmaceutical and Janssen Pharmaceuticals, Inc. For more information visit

Media and Investor Contacts:
Russo Partners
Ian Stone or David Schull (media)
(619) 308-6541 or (212) 845-4271

Cindy McGee (investors)
(619) 308-6538

SOURCE Receptos Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Receptos Achieves Milestone Under License of G-Protein Coupled Receptor Crystal Structure Determination Technology
2. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
3. AXIOS™ Stent and Delivery System Study Demonstrates Successful Treatment of Pancreatic Pseudocysts and Acute Cholecystitis
4. Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
5. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
6. Sustained Growth Forecast for Medical Devices and Drug Delivery Markets According to New Market Research Available from Global Information Inc.
7. VICAMs New Fumo-V Strip Tests Delivers Accurate Detection of Fumonisin Mycotoxins in Minutes
8. FDA Clears Expanded Compatibility for INOMAX® Drug-Delivery Systems
9. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Annual Report
10. Medical Device Study Delivers Marketing Budget and Staffing Metrics to Promote Efficient Use of Resources
11. Delcath Announces Agreement With Institut Gustave Roussy for Launch of Hepatic CHEMOSAT Delivery System in France
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... has found that immunotherapy can be efficiently ...
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Japanese ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and Markets ... "Advanced Wound Care Market by Type (Dressings, Therapy ... User (In-Patient Facility, Out-Patient Facility), and Geography - Global ... --> --> The ... definition and forecast of the global advanced wound care ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 2015 , ... The print component of “Supporting Our Caregivers” ... New York, Minneapolis, South Florida, with a circulation of approximately 250,000 copies and ... vast social media strategy and across a network of top news sites and ...
(Date:11/27/2015)... ... 2015 , ... A simply groundbreaking television series, "Voices in America", which is ... an array of issues that are presently affecting Americans. Dedicated to providing the world ... is changing the subjects consumers focus on, one episode at a time. , ...
(Date:11/27/2015)... Rosa, CA (PRWEB) , ... November 27, 2015 , ... ... Northern California Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at ... meeting. They observed that both STEMI and Sepsis conditions present in similar ways and ...
(Date:11/26/2015)... ON (PRWEB) , ... November 26, 2015 , ... ... of a real-time eReferral system for diagnostic imaging in the Waterloo region. Using ... BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) without ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... process, participated in the 61st annual Employee Benefits Conference. The Employee Benefits Conference ... Sunday, November 8th through Wednesday, November 11th, 2015. The conference was held at ...
Breaking Medicine News(10 mins):